Main / Medical products / Vartocid
A topical immunomodulator
to remove genital warts in men and women
Vartocid® is a Russian generic drug designed to treat genital and perianal external warts in adults. It is able to reduce the size of anogenital warts and/or ensure their complete removal with the minimal risk of recurrence. The drug contains imiquimod — an immunomodulator, which has widely been used in the USA, Germany, France, UK, Italy, Japan and other countries for 15 years already. Now it is also available to Russian patients.
In terms of chemical properties and specific activity rates Vartocid® corresponds to the original medicine Imiquimod Cream 5% (Aldara®) manufactured by 3M Pharmaceutical (USA).
The active substance of Vartocid® is imiquimod (lat. Imiquimodum) – a low-molecular derivative of imiquidazole, an immunomodulating agent. This compound is an immune response modifier able to destruct pathologic sites and rectify local immunity. Its international nonproprietary name (INN) is imiquimod.
Imiquimod isn't characterized by direct antiviral activity, its action is based on inducing interferon alpha (IFNα), tissue necrosis factor (TNF) and other inflammatory cytokines. Additionally, imiquimod influences the formation of immune reactions necessary for destroying virus-infected and tumor cells; it also destroys the affected cells directly. When administered topically, the agent inhibits angiogenesis processes by means of increasing the production of interleukin-18 and interferon gamma.
Apart from water and the active substance (imiquimod, 5%), the cream composition includes cosmetic and medical additives which provide antibacterial, analgesic, moisturizing and softening effects for the affected skin.
Indications for use
Vartocid® (Imiquimod, 5%) is indicated for treating external genital warts (condylomata acuminata) located at external sex organs and/or perianal area in men and women. It is produced as a 5% cream, which should be applied to the affected area three times a week for the night until warts are completely gone (but for not more than 4 months).
Anogenital warts are caused by human papillomavirus (HPV) infection of a human body. The effects of using Vartocid® (imiquimod, 5%) include anti-inflammatory action, stimulation of interferon excretion and production of large quantities of biologically active substances in the administration area, which allows the body itself to overcome the infection-caused disorder.
Proved clinical efficacy
- Reduction in the number of genital warts and size of the affected area up to complete elimination.
- Reduction in unpleasant sensations (itching, burning) intensity in the affected area; overall condition improvement.>
Vartocid® (imiquimod, 5%) therapy is an effective method of genital warts removal in men and women with ― at present time ― the least frequency of recurrences.
The first 5% imiquimod cream study conducted in the USA in 1990-s showed that 56% of patients who used the cream 3 times a week and 71% of those who used it daily experienced complete elimination of genital warts (14% for placebo). During control follow-ups over a 1 year period, recurrences were detected in 13–19% of patients only (Baker D., et al., 1995; Trofatter K.E., 1997).
These conclusions are generally proved by the results of more contemporary international trials (350 articles including 113 systematic reviews, 2 meta-analyses [Yan et al., 2006; Gotovtseva et al., 2008] and more than 50 randomized, placebo-controlled and open trials) as well as by a single-blind, comparative, randomized, placebo-controlled clinical study of Vartocid® (imiquimod) 5% cream for external use efficacy and safety, conducted by MBSPC Cytomed . Thus, experts working at the State Scientific Center of Dermatology and Cosmetology of the Russian Ministry of Health (Moscow) proved that the clinical effect of Vartocid® therapy was evident in more than 50% of patients, 16% of them experienced the compete regression of warts, while 36% showed significant reduction of the affected dermal area.
According to the data of Russian and international studies focused at imiquimod therapy outcomes, the number of patients showing positive reaction to HPV (human papillomavirus) DNA tests also reduces.
The safety of use is asserted by the absence of considerable adverse events and clinically significant changes
in general blood and urine tests and biochemical blood properties of patients treated with Vartocid®
(imiquimod) cream 5% for external use. The obtained outcomes are fully consistent with published data on imiquimod cream 5% (ALDARA).
Topical side reactions to the product usually develop with daily administration only. There are several factors that limit the use of Vartocid® cream (imiquimod, 5%) in some patient groups (see the drug Label for details).
Vartocid® (imiquimod) cream for external use 5% is a prescription drug, it is available at pharmacies on prescription.
||Number per package
|Cream for external use
||10 g in a tube
|20 g in a tube
The average expenditure of Vartocid®
(imiquimod, 5%) cream for external use is insignificant: approximately 10 mg of cream per 1 cm2 of dermal surface. If administered according to usage recommendations, 1 package (10 g) of the medicine is sufficient to complete a treatment course resulting
in full elimination of warts even in case of a considerable area affected by anogenital (venereal) warts.